Provided is a use of a PD-1 antibody in treating a tumor. In particular, provided is a use of an anti-PD-1 antibody or an antigen-binding fragment thereof in preparing a drug for treating a tumor patient having received treatment with an anti-CTLA-4 antibody or an antigen-binding fragment thereof.